An observational study in Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative and Childhood Acute Lymphoblastic Leukemia, sponsored by Children's Oncology Group. Completed at 192 sites in 6 countries. Open to participants aged Up to 30 Years. Per ClinicalTrials.gov, last updated 2018-07-19.
Sponsored by Children's Oncology Group · Observational
This study is collecting and storing malignant, borderline malignant neoplasms, and related biological samples from young patients with cancer. Collecting and storing samples of tumor tissue, blood, and bone marrow from patients with cancer to study in the laboratory may help the study of cancer in the future.
OBJECTIVES:
I. Collect malignant, borderline malignant neoplasms, and related biological specimens from Children's Oncology Group institutions for cases in which there is no disease-specific biologic protocol.
II. Provide a repository for long-term storage of malignant, borderline malignant neoplasms, and related biological specimens from these patients.
III. Make specimens available to qualified researchers to understand the biology of cancer in these patients.
OUTLINE:
Tumor tissue samples, blood, and bone marrow aspirates are collected and stored for future analysis.
117 studies on the registry are indexed under Leukemia, Biphenotypic, Acute; 51 are open to participants now.
Browse Leukemia, Biphenotypic, Acute studies →Children's Oncology Group is the lead sponsor of 447 studies on the registry; 35 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 11 (92%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Meets any of the following criteria:
Must have biological specimens including solid tumors and leukemias available
Solid tumors meeting the following criteria:
Snap frozen primary tumor OR OCT embedded primary tumor OR formalin fixed (block or tissue in formalin) primary tumor AND at least 10 unstained paraffin slides for NIH Mandated QC (tumors that have undergone central pathology review are allowed)
Pleural fluid or cytologic specimens meeting the following criteria:
At least 1 mL of fluid and at least 2 unstained cytospin slides (or 2 unstained smears)
ALL/AML
Tumor tissue samples, blood, and bone marrow aspirates are collected and stored for future analysis.
Other: Cytology Specimen Collection Procedure
Correlative studies
Also known as: Cytologic Sampling
Repository of malignant, borderline malignant neoplasms, and related biological specimens
Time frame: Baseline
Showing the first 100 of 192 sites across 6 countries.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leukemia, Biphenotypic, Acute →